Jurisdiction - Australia
News
Australia – Risks Of Licensing Your IP.

26 September, 2013

 

 

Recent Australian cases have highlighted that a company licensing its intellectual property (IP) may be exposed to risks of infringing third party’s IP rights from a licensee’s actions.


Some recent Australian patent cases (including Bayer Pharma Aktiengesellschaft v Genentech Inc [2012] FCS 1467 (interlocutory); Apotex Pty Ltd v Les Laboratoires Servier (No 4) [2010] FCA 1202; Apotex Pty Ltd v Les Laboratoires Servier (No 2) [2012] FCA 748) focus on whether the licensor and licensee have shared in a “common design”. The cases show that the risk will be higher for licensors where:

 

  • the licensor is aware of the third party patent;
  • the licensor is involved in the supply chain; 
  • there is joint development of product, or co-ordination of business plans with the licensee; 
  • the licensor is related to the licensee; 
  • the licensor is involved in seeking regulatory approval or otherwise in how the licensed product/process is promoted; or
  • the licensor receives a financial benefit from licensee sales.

 

There are a number of steps which may help mitigate the risk.

 

  • Consider your own searches as licensor and address any risks identified (e.g. develop a workaround or modify the product). 
  • Seek contractual protection from the licensee, including an appropriate indemnity, and an obligation to obtain relevant professional indemnity insurance. 
  • Require the licensee to be solely responsible for bringing the relevant product to market. This may not be commercially appropriate, depending on the nature of the licensor/licensee relationship.
 

 

 

herbert smith Freehills

 

For further information, please contact:

 

Kristin Stammer, Partner, Herbert Smith Freehills
kristin.stammer@hsf.com

 

Amalia Stone, Herbert Smith Freehills
Amalia.Stone@hsf.com

 

Herbert Smith Freehills Intellectual Property Practice Profile in Australia

 

Homegrown Intellectual Property Law Firms in Australia

 

Comments are closed.